osimertinib
astrazeneca
['adaura']
#esmo22 the much-waited 4-year data of adaura: mdfs:65.8 m vs 21.9m hr=0.23 hr=0.24 for cns, 2% probability of cns relapse at 3 years with osi qtc prolong in 9%
osi interrupted at 3 years and curve drops sharply after this landmark, so maybe continue beyond? 
#MedicalOncologist MSc Transl Res Univ Paris Sud   #LungCancer biology, immunotherapy, clinical trials #LCSM @myESMO faculty #OncoAlert   live to give